Interaction of ncRNAs and the PI3K/AKT/mTOR pathway: Implications for osteosarcoma

被引：0

作者：

Shao, Weilin ^{[1
]}

Feng, Yan ^{[1
]}

Huang, Jin ^{[1
]}

Li, Tingyu ^{[3
]}

Gao, Shengguai ^{[3
]}

Yang, Yihao ^{[1
]}

Li, Dongqi ^{[1
]}

Yang, Zuozhang ^{[1
]}

Yao, Zhihong ^{[1
,2
]}

机构：

[1] Kunming Med Univ, Yunnan Canc Hosp, Bone & Soft Tissue Tumours Res Ctr Yunnan Prov, Yunnan Canc Ctr,Affiliated Hosp 3,Dept Orthopaed, 519 Kunzhou Rd, Kunming 650118, Yunnan, Peoples R China

[2] Kunming Med Univ, Yunnan Canc Hosp, Yunnan Canc Ctr, Affiliated Hosp 3,Dept Canc,Res Inst, 519 Kunzhou Rd, Kunming 650118, Yunnan, Peoples R China

[3] Kunming Med Univ, Clin Oncol Inst, Kunming 650500, Yunnan, Peoples R China

来源：

OPEN LIFE SCIENCES | 2024年 / 19卷 / 01期

基金：

美国国家科学基金会;

关键词：

osteosarcoma; PI3K/AKT/mTOR; ncRNAs; biomarkers; therapeutic targets; PROMOTES CELL-PROLIFERATION; SIGNALING PATHWAY; NONCODING RNA; CISPLATIN RESISTANCE; DOWN-REGULATION; TUMOR PROGRESSION; CIRCULAR RNAS; UP-REGULATION; GROWTH; INVASION;

D O I：

10.1515/biol-2022-0936

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Osteosarcoma (OS) is the most common primary malignant bone tumor in children and adolescents, and is characterized by high heterogeneity, high malignancy, easy metastasis, and poor prognosis. Recurrence, metastasis, and multidrug resistance are the main problems that limit the therapeutic effect and prognosis of OS. PI3K/AKT/mTOR signaling pathway is often abnormally activated in OS tissues and cells, which promotes the rapid development, metastasis, and drug sensitivity of OS. Emerging evidence has revealed new insights into tumorigenesis through the interaction between the PI3K/AKT/mTOR pathway and non-coding RNAs (ncRNAs). Therefore, we reviewed the interactions between the PI3K/AKT/mTOR pathway and ncRNAs and their implication in OS. These interactions have the potential to serve as cancer biomarkers and therapeutic targets in clinical applications.

引用

页数：14

共 50 条

[1] PI3K/AKT/mTOR pathway in angiogenesis
Karar, Jayashree
Maity, Amit
FRONTIERS IN MOLECULAR NEUROSCIENCE, 2011, 4
[2] The PI3K/Akt/mTOR signaling pathway
Dennis, P. A.
ANNALS OF ONCOLOGY, 2011, 22 : 19 - 19
[3] Overview of the PI3K/Akt/mTOR pathway
Dennis, P. A.
ANNALS OF ONCOLOGY, 2008, 19 : 21 - 21
[4] The PI3K/AKT/mTOR interactive pathway
Ersahin, Tulin
Tuncbag, Nurcan
Cetin-Atalay, Rengul
MOLECULAR BIOSYSTEMS, 2015, 11 (07) : 1946 - 1954
[5] The PI3K/AKT/mTOR signaling pathway: Implications in the treatment of breast cancer
Andreopoulou E.
Current Breast Cancer Reports, 2011, 3 (1) : 63 - 74
[6] Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
Chen, Jiezhong
Zhao, Kong-Nan
Li, Rui
Shao, Renfu
Chen, Chen
CURRENT MEDICINAL CHEMISTRY, 2014, 21 (26) : 3070 - 3080
[7] RAS Signaling in the PI3K/AKT/MTOR Pathway
Nussinov, Ruth
Zhang, Mingzhen
Jang, Hyunbum
BIOPHYSICAL JOURNAL, 2020, 118 (03) : 51A - 51A
[8] THE PI3K/AKT MTOR PATHWAY IN OLIGODENDROCYTE DIFFERENTIATION
Wood, T.
Tyler, W.
Gangoli, N.
Gokina, P.
Kim, H.
Covey, M.
Levison, S.
GLIA, 2009, 57 (13) : S20 - S20
[9] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
Huemer F.
Bartsch R.
Gnant M.
Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
[10] PI3K/AKT/mTOR
Umemura, Shigeki
Goto, Koichi
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S116 - S117

← 1 2 3 4 5 →